Limits...
Prospective monitoring reveals dynamic levels of T cell immunity to Mycobacterium tuberculosis in HIV infected individuals.

Mitchell JE, Chetty S, Govender P, Pillay M, Jaggernath M, Kasmar A, Ndung'u T, Klenerman P, Walker BD, Kasprowicz VO - PLoS ONE (2012)

Bottom Line: During follow-up 30 individuals were placed on ARVs and 4 progressed to active TB.Fluctuations in SFC did not correlate with CD4 count, viral load, treatment initiation, or progression to active TB.The RD1-Elispot appears to have limited value in this setting.

View Article: PubMed Central - PubMed

Affiliation: Ragon Institute of MGH, Harvard Medical School, Boston, Massachusetts, United States of America.

ABSTRACT
Monitoring of latent Mycobacterium tuberculosis infection may prevent disease. We tested an ESAT-6 and CFP-10-specific IFN-γ Elispot assay (RD1-Elispot) on 163 HIV-infected individuals living in a TB-endemic setting. An RD1-Elispot was performed every 3 months for a period of 3-21 months. 62% of RD1-Elispot negative individuals were positive by cultured Elispot. Fluctuations in T cell response were observed with rates of change ranging from -150 to +153 spot-forming cells (SFC)/200,000 PBMC in a 3-month period. To validate these responses we used an RD1-specific real time quantitative PCR assay for monokine-induced by IFN-γ (MIG) and IFN-γ inducible protein-10 (IP10) (MIG: r=0.6527, p=0.0114; IP-10: r=0.6967, p=0.0056; IP-10+MIG: r=0.7055, p=0.0048). During follow-up 30 individuals were placed on ARVs and 4 progressed to active TB. Fluctuations in SFC did not correlate with CD4 count, viral load, treatment initiation, or progression to active TB. The RD1-Elispot appears to have limited value in this setting.

Show MeSH

Related in: MedlinePlus

Longitudinal MTB-specific T cell profiles and correlation with CD4 count and HIV viral load.Longitudinal Elispot data from individuals who were not on ARVs for the entire period of follow-up. Figure 2A: Examples of responses from 3 individuals who were ex vivo RD1-Elispot positive at all time-points during follow-up. Figure 2B: Examples of responses from 3 individuals who displayed an RD1-Elispot conversion that was sustained during follow-up and examples of responses from 3 individuals who displayed a transient RD1-Elispot conversion during follow-up. Figure 2C: Examples of responses from 3 individuals who displayed a transient RD1-Elispot reversion during follow-up. Left-hand panel =  Elispot data, right-hand panel  =  CD4 counts and viral loads.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3369919&req=5

pone-0037920-g002: Longitudinal MTB-specific T cell profiles and correlation with CD4 count and HIV viral load.Longitudinal Elispot data from individuals who were not on ARVs for the entire period of follow-up. Figure 2A: Examples of responses from 3 individuals who were ex vivo RD1-Elispot positive at all time-points during follow-up. Figure 2B: Examples of responses from 3 individuals who displayed an RD1-Elispot conversion that was sustained during follow-up and examples of responses from 3 individuals who displayed a transient RD1-Elispot conversion during follow-up. Figure 2C: Examples of responses from 3 individuals who displayed a transient RD1-Elispot reversion during follow-up. Left-hand panel =  Elispot data, right-hand panel  =  CD4 counts and viral loads.

Mentions: Longitudinal Elispot data from individuals who were not on ARVs for the entire period of follow-up. Figure 2A: Examples of responses from 3 individuals who were ex vivo RD1-Elispot positive at all time-points during follow-up. Figure 2B: Examples of responses from 3 individuals who displayed an RD1-Elispot conversion that was sustained during follow-up and examples of responses from 3 individuals who displayed a transient RD1-Elispot conversion during follow-up. Figure 2C: Examples of responses from 3 individuals who displayed a transient RD1-Elispot reversion during follow-up. Left-hand panel =  Elispot data, right-hand panel  =  CD4 counts and viral loads.


Prospective monitoring reveals dynamic levels of T cell immunity to Mycobacterium tuberculosis in HIV infected individuals.

Mitchell JE, Chetty S, Govender P, Pillay M, Jaggernath M, Kasmar A, Ndung'u T, Klenerman P, Walker BD, Kasprowicz VO - PLoS ONE (2012)

Longitudinal MTB-specific T cell profiles and correlation with CD4 count and HIV viral load.Longitudinal Elispot data from individuals who were not on ARVs for the entire period of follow-up. Figure 2A: Examples of responses from 3 individuals who were ex vivo RD1-Elispot positive at all time-points during follow-up. Figure 2B: Examples of responses from 3 individuals who displayed an RD1-Elispot conversion that was sustained during follow-up and examples of responses from 3 individuals who displayed a transient RD1-Elispot conversion during follow-up. Figure 2C: Examples of responses from 3 individuals who displayed a transient RD1-Elispot reversion during follow-up. Left-hand panel =  Elispot data, right-hand panel  =  CD4 counts and viral loads.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3369919&req=5

pone-0037920-g002: Longitudinal MTB-specific T cell profiles and correlation with CD4 count and HIV viral load.Longitudinal Elispot data from individuals who were not on ARVs for the entire period of follow-up. Figure 2A: Examples of responses from 3 individuals who were ex vivo RD1-Elispot positive at all time-points during follow-up. Figure 2B: Examples of responses from 3 individuals who displayed an RD1-Elispot conversion that was sustained during follow-up and examples of responses from 3 individuals who displayed a transient RD1-Elispot conversion during follow-up. Figure 2C: Examples of responses from 3 individuals who displayed a transient RD1-Elispot reversion during follow-up. Left-hand panel =  Elispot data, right-hand panel  =  CD4 counts and viral loads.
Mentions: Longitudinal Elispot data from individuals who were not on ARVs for the entire period of follow-up. Figure 2A: Examples of responses from 3 individuals who were ex vivo RD1-Elispot positive at all time-points during follow-up. Figure 2B: Examples of responses from 3 individuals who displayed an RD1-Elispot conversion that was sustained during follow-up and examples of responses from 3 individuals who displayed a transient RD1-Elispot conversion during follow-up. Figure 2C: Examples of responses from 3 individuals who displayed a transient RD1-Elispot reversion during follow-up. Left-hand panel =  Elispot data, right-hand panel  =  CD4 counts and viral loads.

Bottom Line: During follow-up 30 individuals were placed on ARVs and 4 progressed to active TB.Fluctuations in SFC did not correlate with CD4 count, viral load, treatment initiation, or progression to active TB.The RD1-Elispot appears to have limited value in this setting.

View Article: PubMed Central - PubMed

Affiliation: Ragon Institute of MGH, Harvard Medical School, Boston, Massachusetts, United States of America.

ABSTRACT
Monitoring of latent Mycobacterium tuberculosis infection may prevent disease. We tested an ESAT-6 and CFP-10-specific IFN-γ Elispot assay (RD1-Elispot) on 163 HIV-infected individuals living in a TB-endemic setting. An RD1-Elispot was performed every 3 months for a period of 3-21 months. 62% of RD1-Elispot negative individuals were positive by cultured Elispot. Fluctuations in T cell response were observed with rates of change ranging from -150 to +153 spot-forming cells (SFC)/200,000 PBMC in a 3-month period. To validate these responses we used an RD1-specific real time quantitative PCR assay for monokine-induced by IFN-γ (MIG) and IFN-γ inducible protein-10 (IP10) (MIG: r=0.6527, p=0.0114; IP-10: r=0.6967, p=0.0056; IP-10+MIG: r=0.7055, p=0.0048). During follow-up 30 individuals were placed on ARVs and 4 progressed to active TB. Fluctuations in SFC did not correlate with CD4 count, viral load, treatment initiation, or progression to active TB. The RD1-Elispot appears to have limited value in this setting.

Show MeSH
Related in: MedlinePlus